Reich, Kristian http://orcid.org/0000-0001-5248-4332
Bianchi, Luca
Khemis, Abdallah
Maul, Julia-Tatjana
Tsianakas, Athanasios
Schempp, Christoph M.
Petersen, Kim
Noergaard, Mia M.
Puig, Lluis
Clinical trials referenced in this document:
Documents that mention this clinical trial
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
https://doi.org/10.1007/s13555-023-01092-x
Article History
Received: 27 November 2023
Accepted: 18 December 2023
First Online: 1 February 2024
Declarations
:
: K Reich has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi, UCB; Professor Reich is co-founder of Moonlake Immunotherapeutics. L Bianchi has been a consultant for and/or has received honoraria and/or investigator fees from AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB Pharma. A Khemis has been a consultant for and/or has received honoraria and/or investigator fees from AbbVie, Actelion, Almirall, Amgen, Basilea, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Forward Pharma, GlaxoSmithKline, Galderma, Genentec, Janssen, La Roche Posay, LEO Pharma, Medac, Merck Sharp & Dohme, Novartis, Pierre Fabre Dermatologie, Pfizer, Regeneron, Roche, Sanofi and UCB Pharma. JT Maul has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and UCB. A Tsianakas has received honoraria and investigator fees from LEO Pharma A/S. CM Schempp has been a consultant for and/or has received honoraria and/or investigator fees from Abbvie Inc, Allmirall, Biofrontera, Boehringer Ingelheim, Birken AG, CassellaMed GmbH & Co KG, Celgene GmbH, Essex Pharma GmbH, Janssen-Cilag GmbH, LEO Pharma A/S, Medac, Novartis AG, Lilly GmbH, Pfizer, Sanofi Regeneron, Therakos, UCB Pharma. K Petersen and MM Noergaard are employees of LEO Pharma A/S. L Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, LEO Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB.
: The trial was conducted in accordance with the Declaration of Helsinki and ICH GCP, including archiving of essential documents. The trial protocol was approved by the institutional review boards/ethics committees before commencement and patients provided written informed consent before trial-related procedures.